Oral convenience vs injectable cleanliness. Two paths to the same hormone, very different side-effect profiles.
| MK-677 | Ipamorelin | |
|---|---|---|
| Class | Oral ghrelin-mimetic small molecule | Injectable pentapeptide |
| Route | Oral capsule or liquid | Subcutaneous injection |
| Half-life | ~24 hours | ~2 hours |
| Dose frequency | Once daily | 2-3× daily (or stacked w/ CJC-1295) |
| Typical dose | 10-25 mg / day | 200-300 mcg / dose |
| Appetite increase | Significant | Minimal |
| Water retention | Significant | Minimal |
| Cortisol / prolactin | Minimal | None |
| Sleep effect | Strong | Strong |
| Insulin sensitivity | Decreases over time | No change |
MK-677 is the only oral, once-daily GH secretagogue with real clinical data behind it. That convenience is the dominant reason people choose it over injectables. The price you pay: appetite stimulation, water retention, and insulin-sensitivity decline over long cycles.
Among the GHRPs, ipamorelin is uniquely "clean" — it produces a strong, selective GH pulse without elevating cortisol, prolactin, or aldosterone. It also has minimal appetite effect. The cost: short half-life (~2 hours), so it needs multiple daily doses or a CJC-1295 partner.
MK-677 is typically run for 8-12 weeks with 4-8 weeks off, because of receptor desensitization and the water/insulin issues. Ipamorelin (stacked with CJC-1295) is often run longer — 12-16 weeks — because of its cleaner side-effect profile.
Pick MK-677 if oral convenience is the priority and you can manage the water/appetite. Pick ipamorelin (with CJC-1295) if you want the cleanest GH pulse, can manage daily injections, and need to avoid the metabolic side effects.
Epti lets you log your protocol — every dose, side-effect, and outcome on one timeline. The only way to know which works for you.